摘要
目的 进一步探讨新辅助化疗对Ⅲ期乳腺癌的临床疗效及 5年生存率的影响。方法 将手术后的 80例Ⅲ期乳腺癌分为A组、B组。A组为CMF方案化疗 3周期后 ,1周内手术 ,B组为术前未施化疗组。手术均为改良根治术 ,术后常规综合治疗。结果 A组 5年生存率 (73% ) ,明显高于B组 (2 9% ) ,差异具有显著性P <0 .0 5。化疗有效组 5年生存率高于化疗无效组。
Objective To study the effect of neoadjuvant chemotherapy(NACT) on Ⅲ stage breast cancer. Methods Eighty patients were randomized to group A (45patients) and group B (35patients), Group A are treated by CMF for 3 cycles before operations, modify radical operation were adopted. Similarly therapy have been performed on both groups after operations. Results The 5 years survival rate (5 years) of group A is significantly higher than that in group B ( P < 0.05 ). The 5 years of patients who are sensitive to CMF are better than the others. Conclusion We think that the effective neoadjuvant chemotherapy can improve the 5 years of Ⅲ stage breast cancer patients.
出处
《肿瘤防治研究》
CAS
CSCD
2003年第3期221-222,共2页
Cancer Research on Prevention and Treatment
